Base de dados : MEDLINE
Pesquisa : D03.383.129.578.075 [Categoria DeCS]
Referências encontradas : 5755 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 576 ir para página                         

  1 / 5755 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450174
[Au] Autor:Ribeiro NQ; Costa MC; Magalhães TFF; Carneiro HCS; Oliveira LV; Fontes ACL; Santos JRA; Ferreira GF; Araujo GRS; Alves V; Frases S; Paixão TA; de Resende Stoianoff MA; Santos DA
[Ad] Endereço:Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Minas Gerais, Brazil.
[Ti] Título:Atorvastatin as a promising anticryptococcal agent.
[So] Source:Int J Antimicrob Agents;49(6):695-702, 2017 Jun.
[Is] ISSN:1872-7913
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cryptococcosis caused by Cryptococcus gattii leads to pneumonia and meningoencephalitis, and has a high mortality rate worldwide due to the inadequacy of available therapy and increasing drug resistance. There is a need to develop effective treatments, and drug repositioning is an interesting alternative to achieve new strategies to treat cryptococcosis. Atorvastatin (ATO), a statin currently used to treat hypercholesterolaemia, was tested in this study as an adjuvant to control infections caused by C. gattii. Several aspects of the effect of ATO on the host and the yeast were evaluated, with particular focus on the association of ATO with fluconazole (FLC), which (i) reduced ergosterol content in the cell membrane and altered properties of the polysaccharide capsule of C. gattii; (ii) increased the production of reactive oxygen species by macrophages; and (iii) reduced yeast phagocytosis and the intracellular proliferation rate. In an animal model, infected mice treated with ATO + FLC showed increased survival, improved clinical condition, and reduced fungal burden in the lungs and brain. This study is the first to perform in vivo tests with ATO + FLC for the treatment of cryptococcosis. The results suggest that ATO may be an important adjuvant for the treatment of cryptococcosis.
[Mh] Termos MeSH primário: Anticolesterolemiantes/uso terapêutico
Antifúngicos/uso terapêutico
Atorvastatina Cálcica/uso terapêutico
Criptococose/tratamento farmacológico
Cryptococcus gattii/efeitos dos fármacos
Reposicionamento de Medicamentos
[Mh] Termos MeSH secundário: Animais
Anticolesterolemiantes/farmacologia
Antifúngicos/farmacologia
Atorvastatina Cálcica/farmacologia
Criptococose/microbiologia
Modelos Animais de Doenças
Quimioterapia Combinada/métodos
Fluconazol/farmacologia
Fluconazol/uso terapêutico
Masculino
Camundongos Endogâmicos C57BL
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Antifungal Agents); 48A5M73Z4Q (Atorvastatin Calcium); 8VZV102JFY (Fluconazole)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29217137
[Au] Autor:Broniarek I; Jarmuszkiewicz W
[Ad] Endereço:Department of Bioenergetics, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University in Poznan, Poland.
[Ti] Título:Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria.
[So] Source:Arch Biochem Biophys;637:64-72, 2018 01 01.
[Is] ISSN:1096-0384
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this research was to elucidate the direct effects of two popular blood cholesterol-lowering drugs used to treat cardiovascular diseases, atorvastatin and pravastatin, on respiratory function, membrane potential, and reactive oxygen species formation in mitochondria isolated from human umbilical vein endothelial cells (EA.hy926 cell line). Hydrophilic pravastatin did not significantly affect endothelial mitochondria function. In contrast, hydrophobic calcium-containing atorvastatin induced a loss of outer mitochondrial membrane integrity, an increase in hydrogen peroxide formation, and reductions in maximal (phosphorylating or uncoupled) respiratory rate, membrane potential and oxidative phosphorylation efficiency. The atorvastatin-induced changes indicate an impairment of mitochondrial function at the level of ATP synthesis and at the level of the respiratory chain, likely at complex I and complex III. The atorvastatin action on endothelial mitochondria was highly dependent on calcium ions and led to a disturbance in mitochondrial calcium homeostasis. Uptake of calcium ions included in atorvastatin molecule induced mitochondrial uncoupling that enhanced the inhibition of the mitochondrial respiratory chain by atorvastatin. Our results indicate that hydrophobic calcium-containing atorvastatin, widely used as anti-atherosclerotic agent, has a direct negative action on isolated endothelial mitochondria.
[Mh] Termos MeSH primário: Atorvastatina Cálcica/toxicidade
Inibidores de Hidroximetilglutaril-CoA Redutases/toxicidade
Mitocôndrias/efeitos dos fármacos
Mitocôndrias/metabolismo
Respiração/efeitos dos fármacos
[Mh] Termos MeSH secundário: Cálcio/metabolismo
Transporte de Elétrons/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Potencial da Membrana Mitocondrial/efeitos dos fármacos
Membranas Mitocondriais/efeitos dos fármacos
Membranas Mitocondriais/metabolismo
Fosforilação Oxidativa/efeitos dos fármacos
Consumo de Oxigênio/efeitos dos fármacos
Pravastatina/toxicidade
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Reactive Oxygen Species); 48A5M73Z4Q (Atorvastatin Calcium); KXO2KT9N0G (Pravastatin); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  3 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29279527
[Au] Autor:Ishikawa Y; Itoh T; Satoh M; Fusazaki T; Sugawara S; Nakajima S; Nakamura M; Morino Y
[Ad] Endereço:Division of Cardiology, Department of Internal Medicine, Iwate Medical University.
[Ti] Título:Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome.
[So] Source:Int Heart J;59(1):27-34, 2018 Jan 27.
[Is] ISSN:1349-3299
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Statins can be differentiated into two types, based on their solubility, which have potentially differing effects on the coronary artery wall. However, suspected differences in statins' effects on plaque composition have not been systemically investigated.Sixty-seven patients with acute coronary syndrome (ACS) were randomly assigned to either atorvastatin (10 mg/day) or rosuvastatin (2.5 mg/day). Intravascular ultrasound (IVUS) and integrated backscatter (IB)-IVUS, an established tool to quantify each plaque's components, were performed immediately after emergent percutaneous coronary intervention (PCI). Follow-up IVUS was performed between 6 and 12 months after PCI. Serial changes in serum lipid profiles and plaque composition volumes were compared between the two groups.Thirty-five patients were eligible for serial IB-IVUS analyses. The mean low-density lipoprotein-cholesterol level significantly decreased in the atorvastatin and rosuvastatin groups (P < 0.001); plaque volumes were also significantly reduced from 82.0 ± 46.2 to 74.9 ± 41.3 mm (P = 0.01) and from 74.7 ± 35.3 to 67.7 ± 27.0 mm (P = 0.02), respectively. IB-IVUS revealed a significant reduction in fibrous volume from 33.8 ± 20.0 to 27.5 ± 14.9 mm (P < 0.01) and from 29.6 ± 13.6 to 24.8 ± 7.6 mm (P < 0.05), respectively; however, significant changes were not noted in the volume of the lipid pool for the atorvastatin group and the rosuvastatin group, respectively.Water- and lipid-soluble statins may be similarly effective in reducing coronary plaques in patients with ACS as judged qualitatively and quantitatively. Further study is needed to determine whether differences between water- and lipid-soluble statins affect plaque components.
[Mh] Termos MeSH primário: Síndrome Coronariana Aguda/tratamento farmacológico
Atorvastatina Cálcica/administração & dosagem
Vasos Coronários/diagnóstico por imagem
Lipídeos/sangue
Placa Aterosclerótica/tratamento farmacológico
Rosuvastatina Cálcica/administração & dosagem
[Mh] Termos MeSH secundário: Síndrome Coronariana Aguda/sangue
Síndrome Coronariana Aguda/diagnóstico por imagem
Idoso
Biomarcadores/sangue
Relação Dose-Resposta a Droga
Feminino
Seguimentos
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Masculino
Meia-Idade
Placa Aterosclerótica/sangue
Placa Aterosclerótica/diagnóstico por imagem
Estudos Prospectivos
Índice de Gravidade de Doença
Fatores de Tempo
Resultado do Tratamento
Ultrassonografia de Intervenção
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Lipids); 48A5M73Z4Q (Atorvastatin Calcium); 83MVU38M7Q (Rosuvastatin Calcium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1536/ihj.16-587


  4 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465323
[Au] Autor:Walker ME; Souza PR; Colas RA; Dalli J
[Ad] Endereço:Lipid Mediator Unit, Centre for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom.
[Ti] Título:13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.
[So] Source:FASEB J;31(8):3636-3648, 2017 08.
[Is] ISSN:1530-6860
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Rheumatoid arthritis is an inflammatory condition characterized by overzealous inflammation that leads to joint damage and is associated with an increased incidence of cardiovascular disease. Statins are frontline therapeutics for patients with cardiovascular disease and exert beneficial actions in rheumatoid arthritis. The mechanism that mediates the beneficial actions of statins in rheumatoid arthritis remains of interest. In the present study, we found that the administration of 2 clinically relevant statins-atorvastatin (0.2 mg/kg) or pravastatin (0.2 mg/kg)-to mice during inflammatory arthritis up-regulated systemic and tissue amounts of a novel family of proresolving mediators, termed 13-series resolvins (RvTs), and significantly reduced joint disease. Of note, administration of simvastatin (0.2 mg/kg) did not significantly up-regulate RvTs or reduce joint inflammation. We also found that atorvastatin and pravastatin each reduced systemic leukocyte activation, including platelet-monocyte aggregates (∼25-60%). These statins decreased neutrophil trafficking to the joint as well as joint monocyte and macrophage numbers. Atorvastatin and pravastatin produced significant reductions (∼30-50%) in expression of CD11b and major histocompatibility complex class II on both monocytes and monocyte-derived macrophages in joints. Administration of an inhibitor to cyclooxygenase-2, the initiating enzyme in the RvT pathway, reversed the protective actions of these statins on both joint and systemic inflammation. Together, these findings provide evidence for the role of RvTs in mediating the protective actions of atorvastatin and pravastatin in reducing local and vascular inflammation, and suggest that RvTs may be useful in measuring the anti-inflammatory actions of statins.-Walker, M. E., Souza, P. R., Colas, R. A., Dalli, J. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.
[Mh] Termos MeSH primário: Anticolesterolemiantes/uso terapêutico
Artrite/tratamento farmacológico
Atorvastatina Cálcica/uso terapêutico
Ácidos Docosa-Hexaenoicos/metabolismo
Inflamação/tratamento farmacológico
Pravastatina/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Artrite/induzido quimicamente
Artrite/metabolismo
Inflamação/induzido quimicamente
Inflamação/metabolismo
Leucócitos/efeitos dos fármacos
Leucócitos/fisiologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 25167-62-8 (Docosahexaenoic Acids); 48A5M73Z4Q (Atorvastatin Calcium); KXO2KT9N0G (Pravastatin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1096/fj.201700268


  5 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337671
[Au] Autor:Stolarczyk M; Apola A; Maslanka A; Kwiecien A; Opoka W
[Ad] Endereço:1Department of Inorganic and Analytical Chemistry Jagiellonian University Medical College, Faculty of Pharmacy 30-688 Kraków, Poland.
[Ti] Título:Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures.
[So] Source:Acta Pharm;67(4):463-478, 2017 Dec 20.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:Applicability of derivative spectrophotometry for the determination of valsartan in the presence of a substance from the group of statins was checked. The obtained results indicate that the proposed method may be effective by using appropriate derivatives: for valsartan and fluvastatin - D1, D2 and D3, for valsartan and pravastatin - D1 and D3, for valsartan and atorvastatin - D2 and D3. The method was characterized by high sensitivity and accuracy. Linearity was maintained in the following ranges: 9.28-32.48 mg mL-1 for valsartan, 8.16-28.56 mg mL-1 f or fluvastatin, 14.40-39.90 mg mL-1 for atorvastatin and 9.60-48.00 mg mL-1 for pravastatin. Determination coefficients were in the range of 0.989-0.999 depending on the analyte and the order of derivative. The precision of the method was high with RSD from 0.1 to 2.5 % and recovery of individual components was within the range of 100 ± 5 %. The developed method was successfully applied to the determination of valsartan combined with fluvastatin, atorvastatin and pravastatin in laboratory prepared mixtures and in pharmaceutical preparations.
[Mh] Termos MeSH primário: Inibidores de Hidroximetilglutaril-CoA Redutases/análise
Espectrofotometria/métodos
Valsartana/análise
[Mh] Termos MeSH secundário: Atorvastatina Cálcica/análise
Ácidos Graxos Monoinsaturados/análise
Indóis/análise
Pravastatina/análise
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fatty Acids, Monounsaturated); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Indoles); 48A5M73Z4Q (Atorvastatin Calcium); 4L066368AS (fluvastatin); 80M03YXJ7I (Valsartan); KXO2KT9N0G (Pravastatin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  6 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454801
[Au] Autor:Bowman L; Chen F; Sammons E; Hopewell JC; Wallendszus K; Stevens W; Valdes- Marquez E; Wiviott S; Cannon CP; Braunwald E; Collins R; Landray MJ; REVEAL Collaborative Group
[Ti] Título:Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
[So] Source:Am Heart J;187:182-190, 2017 05.
[Is] ISSN:1097-6744
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin-based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipoprotein (HDL) cholesterol. However, it is not known if these apparently favorable lipid changes translate into reductions in cardiovascular events. METHODS: The REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy and safety of adding anacetrapib to effective LDL-lowering treatment with atorvastatin for an average of at least 4years among patients with preexisting atherosclerotic vascular disease. The primary assessment is an intention-to-treat comparison among all randomized participants of the effects of allocation to anacetrapib on major coronary events (defined as the occurrence of coronary death, myocardial infarction, or coronary revascularization). RESULTS: Between August 2011 and October 2013, 30,449 individuals in Europe, North America, and China were randomized to receive anacetrapib 100mg daily or matching placebo. Mean (SD) age was 67 (8) years, 84% were male, 88% had a history of coronary heart disease, 22% had cerebrovascular disease, and 37% had diabetes mellitus. At the randomization visit (after at least 8weeks on a protocol-defined atorvastatin regimen), mean plasma LDL cholesterol was 61 (15) mg/dL and HDL cholesterol was 40 (10) mg/dL. INTERPRETATION: The REVEAL trial will provide a robust evaluation of the clinical efficacy and safety of adding anacetrapib to an effective statin regimen. Results are anticipated in 2017.
[Mh] Termos MeSH primário: Anticolesterolemiantes/uso terapêutico
Atorvastatina Cálcica/uso terapêutico
Doença das Coronárias/prevenção & controle
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Oxazolidinonas/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Anticolesterolemiantes/efeitos adversos
HDL-Colesterol/sangue
HDL-Colesterol/efeitos dos fármacos
LDL-Colesterol/sangue
LDL-Colesterol/efeitos dos fármacos
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Análise de Intenção de Tratamento
Masculino
Meia-Idade
Oxazolidinonas/efeitos adversos
Projetos de Pesquisa
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Oxazolidinones); 48A5M73Z4Q (Atorvastatin Calcium); P7T269PR6S (anacetrapib)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  7 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745862
[Au] Autor:Zhang X; Chen X; Zhao W; Zeng C; Luo X; Li W; Li B; Jiang J; Dong Y
[Ad] Endereço:Division of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, ‡Department of Biomedical Engineering, §The Center for Clinical and Translational Science, ∥The Comprehensive Cancer Center, ⊥Dorothy M. Davis Heart & Lung Research Institute, and ¶Department of Radiation Oncology
[Ti] Título:GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization.
[So] Source:Bioconjug Chem;28(8):2109-2113, 2017 08 16.
[Is] ISSN:1520-4812
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Targeting ligands facilitate cell specific drug delivery and improve pharmaceutical properties. Herein, we designed two ligand drug conjugates by conjugating GlcNAc (N-acetylglucosamine) with atorvastatin. These two conjugates, termed G-AT and G-K-AT, exhibited enhanced water solubility and cellular uptake. Moreover, both G-AT and G-K-AT were able to release atorvastatin and consequently achieve significant inhibition against 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase.
[Mh] Termos MeSH primário: Acetilglucosamina/química
Atorvastatina Cálcica/química
Atorvastatina Cálcica/metabolismo
Água/química
[Mh] Termos MeSH secundário: Transporte Biológico
Linhagem Celular
Seres Humanos
Solubilidade
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
059QF0KO0R (Water); 48A5M73Z4Q (Atorvastatin Calcium); V956696549 (Acetylglucosamine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1021/acs.bioconjchem.7b00295


  8 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28881028
[Au] Autor:Guirao V; Martí-Sistac O; DeGregorio-Rocasolano N; Ponce J; Dávalos A; Gasull T
[Ad] Endereço:Cellular and Molecular Neurobiology Research Group, Department of Neurosciences, Germans Trias i Pujol Research Institute, Badalona, Catalonia, Spain.
[Ti] Título:Specific rescue by ortho-hydroxy atorvastatin of cortical GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB.
[So] Source:J Neurochem;143(3):359-374, 2017 Nov.
[Is] ISSN:1471-4159
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The statin atorvastatin (ATV) given as a post-treatment has been reported beneficial in stroke, although the mechanisms involved are not well understood so far. Here, we investigated in vitro the effect of post-treatment with ATV and its main bioactive metabolite ortho-hydroxy ATV (o-ATV) on neuroprotection after oxygen and glucose deprivation (OGD), and the role of the pro-survival cAMP response element-binding protein (CREB). Post-OGD treatment of primary cultures of rat cortical neurons with o-ATV, but not ATV, provided neuroprotection to a specific subset of cortical neurons that were large and positive for glutamic acid decarboxylase (large-GAD neurons, GABAergic). Significantly, only these GABAergic neurons showed an increase in phosphorylated CREB (pCREB) early after neuronal cultures were treated post-OGD with o-ATV. We found that o-ATV, but not ATV, increased the neuronal uptake of glutamate from the medium; this provides a rationale for the specific effect of o-ATV on pCREB in large-GABAergic neurons, which have a higher ratio of synaptic (pCREB-promoting) vs extrasynaptic (pCREB-reducing) N-methyl-D-aspartate (NMDA) receptors (NMDAR) than that of small-non-GABAergic neurons. When we pharmacologically increased pCREB levels post-OGD in non-GABAergic neurons, through the selective activation of synaptic NMDAR, we observed as well long-lasting neuronal survival. We propose that the statin metabolite o-ATV given post-OGD boosts the intrinsic pro-survival factor pCREB in large-GABAergic cortical neurons in vitro, this contributing to protect them from OGD.
[Mh] Termos MeSH primário: Atorvastatina Cálcica/análogos & derivados
Hipóxia Celular/efeitos dos fármacos
Córtex Cerebral/citologia
Neurônios GABAérgicos/efeitos dos fármacos
Glucose/deficiência
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia
[Mh] Termos MeSH secundário: Animais
Atorvastatina Cálcica/farmacologia
Proteína de Ligação a CREB/metabolismo
Morte Celular/efeitos dos fármacos
Células Cultivadas
Embrião de Mamíferos
Feminino
Ácido Glutâmico/farmacocinética
Masculino
Proteínas do Tecido Nervoso/metabolismo
Ratos
Ratos Sprague-Dawley
Receptores de N-Metil-D-Aspartato/metabolismo
Trítio/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-hydroxyatorvastatin); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Nerve Tissue Proteins); 0 (Receptors, N-Methyl-D-Aspartate); 10028-17-8 (Tritium); 3KX376GY7L (Glutamic Acid); 48A5M73Z4Q (Atorvastatin Calcium); EC 2.3.1.48 (CREB-Binding Protein); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE
[do] DOI:10.1111/jnc.14210


  9 / 5755 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802576
[Au] Autor:Melendez QM; Wooten CJ; Lopez D
[Ad] Endereço:Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), College of Arts and Sciences, North Carolina Central University, Durham, NC, 27707, USA.
[Ti] Título:Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells.
[So] Source:Biochem Biophys Res Commun;492(1):103-108, 2017 Oct 07.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Statins are the first-line treatment for hypercholesterolemic patients. Herein, the effects of three statins on complex formation between proprotein convertase subtilisin-kexin 9 (PCSK9) and the low density lipoprotein receptor (LDLR), a critical step for the PCSK9-dependent degradation of LDLR in the lysosome, were examined. Human hepatocyte-like C3A cells grown in control (containing 10% fetal bovine serum) or MITO+ (supplemented with BD™ MITO + serum extender) medium were also treated with atorvastatin (Atorv), lovastatin (Lov), or pravastatin (Prav) for 24 h. RNA and protein expression studies and determinations of PCSK9/LDLR complex formation were performed. As expected, the statins increased the expression of PCSK9 and LDLR independently of the medium employed. Interestingly, Atov and Lov caused increases in PCSK9/LDLR complex formation, whereas Prav decreased complex formation when compared to cells treated without drugs. These results may explain why Prav works better for statin intolerant patients than other statins such as Atorv and Lov.
[Mh] Termos MeSH primário: Atorvastatina Cálcica/farmacologia
Lovastatina/farmacologia
Pravastatina/farmacologia
Pró-Proteína Convertase 9/antagonistas & inibidores
Pró-Proteína Convertase 9/biossíntese
Receptores de LDL/antagonistas & inibidores
Receptores de LDL/biossíntese
[Mh] Termos MeSH secundário: Células Cultivadas
Seres Humanos
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, LDL); 48A5M73Z4Q (Atorvastatin Calcium); 9LHU78OQFD (Lovastatin); EC 3.4.21.- (PCSK9 protein, human); EC 3.4.21.- (Proprotein Convertase 9); KXO2KT9N0G (Pravastatin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  10 / 5755 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28796030
[Au] Autor:Ma H; Liu Y; Xie H; Zhang G; Zhan H; Liu Z; Wang P; Geng Q; Guo L
[Ad] Endereço:aCardic Rehabilitation Department, Guangdong Cardiovascular Institute, Guangdong General Hospital bGuangdong Academy of Medical Sciences, Guangdong, China.
[Ti] Título:The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study.
[So] Source:Medicine (Baltimore);96(32):e7351, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Some statins, such as atorvastatin, have proven renoprotective effects. The comparative renoprotective potential of simvastatin is less clear. This study aimed to compare the renoprotective effects of simvastatin with atorvastatin in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). This observational study examined the medical records of 271 patients who were treated at the Guangdong Cardiovascular Institute from April 2004 to February 2008. Patients had received either 40 mg simvastatin (n = 128) or 20 mg atorvastatin (n = 143), daily, for a period of at least 6 months following PCI. Declined renal function (DRF) was defined at the occurrence of chronic kidney disease (CKD) or elevated CKD stages at 6-months post-PCI. Results showed that the incidence of DRF was similar among patients taking simvastatin or atorvastatin (25.00% vs 26.57%, respectively). Kaplan-Meier survival analysis showed that patients who developed DRF had a higher incidence of mortality and major adverse cardiovascular events (MACEs) than those without DRF (17.41% vs 28.57%, P = .0308). Multivariate logistic regression analysis identified diabetes and baseline estimated glomerular filtration rate as independent risk factors for DRF. Collectively, our results indicate that simvastatin has comparable renoprotective effects to atorvastatin in ACS patients undergoing PCI. Further studies are warranted to confirm the comparative renoprotective effects of statins.
[Mh] Termos MeSH primário: Síndrome Coronariana Aguda/cirurgia
Atorvastatina Cálcica/administração & dosagem
Intervenção Coronária Percutânea/efeitos adversos
Insuficiência Renal Crônica/etiologia
Insuficiência Renal Crônica/prevenção & controle
Sinvastatina/administração & dosagem
[Mh] Termos MeSH secundário: Síndrome Coronariana Aguda/epidemiologia
Idoso
Diabetes Mellitus/epidemiologia
Feminino
Taxa de Filtração Glomerular
Seres Humanos
Estimativa de Kaplan-Meier
Testes de Função Renal
Modelos Logísticos
Masculino
Meia-Idade
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
48A5M73Z4Q (Atorvastatin Calcium); AGG2FN16EV (Simvastatin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170827
[Lr] Data última revisão:
170827
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007351



página 1 de 576 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde